Company:  GT BIOPHARMA, INC. (GTBP)
Form Type:  10-Q
Filing Date:  11/14/2019 
CIK:  0000109657 
Address:  310 N. WESTLAKE BLVD.
SUITE 206
 
City, State, Zip:  WESTLAKE VILLAGE, California 91362 
Telephone:  (800) 304-9888 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$0.20  
Change: 
0.00 (-0.05%)  
Trade Time: 
Aug 11  
Market Cap: 
$15.31M
Trade GTBP now with 

© 2020  
Description of Business
We are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products based off our proprietary Tri-specific Killer Engager (TriKE(TM)), Tetra-specific Killer Engager (TetraKE(TM)) and bi-specific ligand-directed single-chain fusion protein technology platforms. Our TriKE and TetraKE platforms generate proprietary therapeutics designed to harness and enhance the cancer killing abilities of a patient's own natural killer cells, or NK cells. Once bound to an NK cell, our moieties are designed to enhance the NK cell, and precisely direct it to one or more specifically-targeted proteins expressed on a specific type of cancer cell or virus infected cell, ultimately resulting in the targeted cell's death.
Register and access this filing in:     
  FORM 10-Q
    PART I FINANCIAL INFORMATION ...
      FINANCIAL STATEMENTS
        INCOME STATEMENT
        CASH FLOW
        CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      Item 2. Management's Discussion and Analysis of Financial ...
      Item 3. Quantitative and Qualitative Disclosures About ...
      Item 4. Controls and Procedures
    PART II. OTHER INFORMATION
      Item 1. Legal Proceedings
      Item 1A. Risk Factors
      Item 2. Unregistered Sales of Securities and Use of Proceeds
      Item 3. Defaults Upon Senior Securities.
      Item 4. Mine Safety Disclosures
      Item 5. Other Information.
      Item 6. Exhibits
    SIGNATURES
  EXHIBIT 31.1
    CERTIFICATIONS
  EXHIBIT 31.2
    CERTIFICATIONS
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO
  EXHIBIT 32.2
    CERTIFICATION PURSUANT TO